Allergen-specific immunoglobulin A (sIgA)

Allergen-specific immunoglobulin A (IgA) is a specialized class of antibodies that plays a pivotal role in maintaining immune homeostasis and inducing tolerance toward environmental and dietary allergens. Primarily localized at mucosal surfaces as secretory IgA (sIgA) or circulating as systemic IgA1 and IgA2, these antibodies function as "blocking antibodies" by outcompeting allergen-specific IgE for binding sites on allergens. This competitive inhibition prevents the cross-linking of high-affinity IgE receptors (FcεRI) on mast cells and basophils, effectively neutralizing the allergic cascade and inhibiting the release of inflammatory mediators like histamine. Recent research also suggests that IgA provides active inhibitory signals to immune cells, potentially reducing the phosphorylation of signaling molecules like Syk through receptor-mediated mechanisms. The induction of allergen-specific IgA, particularly the IgA2 subclass, is a primary goal of successful allergen immunotherapy (AIT) and serves as a critical biomarker for clinical desensitization and long-term tolerance. While currently not a direct target of inhibitory small molecules, its role as a therapeutic effect-mediator and a candidate for passive immunization makes it a central focus in modern allergy research.

Other names

Specific IgAAllergen-specific IgASecretory IgAAllergen-specific IgA1Allergen-specific IgA2Blocking IgA

Allergen-specific IgA acts as a blocking antibody that competitively inhibits allergen-IgE binding to prevent FcεRI cross-linking and induces inhibitory signaling in mast cells and basophils via receptor-mediated pathways (potentially involving CD89 or C-type lectins) to suppress degranulation.